Estimated read time 3 min read

HighTide Therapeutics sets sights on HK$278 million in Hong Kong IPO

Chinese biopharmaceutical manufacturer HighTide Therapeutics is gearing up for an initial public offering (IPO) in Hong Kong, with ambitions to raise HK$278 million (US$35.6 million), [more…]

Estimated read time 3 min read

Moody’s downgrade serves as a clear indicator of the mounting concerns surrounding China’s economic challenges

In a significant development, global ratings agency Moody’s has downgraded the outlook on China’s credit rating from “stable” to “negative.” This decision comes on the [more…]